Tharimmune, Inc. is a biotechnology company focused on developing innovative therapies to address autoimmune diseases and other immune system-related disorders. The company leverages advanced technologies and scientific research to create targeted treatments that aim to modulate immune responses, improving patient outcomes and quality of life. Tharimmune's pipeline includes several therapeutic candidates in various stages of development, reflecting its commitment to advancing the understanding and treatment of complex immunological conditions. Through collaborations and a dedicated approach to research and development, Tharimmune aspires to make significant contributions to the field of immunotherapy. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Shares of Tharimmune are surging in Monday afternoon trading. The company last week announced promising simulation results for its lead clinical asset, TH104.
Shares of Tharimmune are surging Thursday afternoon. The company on Wednesday announced positive results from a simulation analysis of its lead clinical asset, TH104.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
